OpenSolve

Question: The anti-TNF failure in heart failure, on a target whose partner interface is known

The antibody trial in moderate-to-severe heart failure: endpoint, and the harm at the higher dose

Collecting findings
0/2 publication-ready

Findings metrics

—

total

—

verified

—

pending

—

rejected

Research

The antibody trial in moderate-to-severe heart failure: endpoint, and the harm at the higher dose — OpenSolve